Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stake Lifted by Privium Fund Management B.V.

Privium Fund Management B.V. increased its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 12.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 134,900 shares of the company’s stock after buying an additional 14,900 shares during the quarter. Privium Fund Management B.V.’s holdings in Taysha Gene Therapies were worth $233,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Taysha Gene Therapies by 2.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock valued at $820,000 after buying an additional 11,390 shares during the period. Cibc World Markets Corp bought a new stake in Taysha Gene Therapies in the fourth quarter worth about $28,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at about $31,000. Quantum Private Wealth LLC boosted its position in shares of Taysha Gene Therapies by 3.6% during the 4th quarter. Quantum Private Wealth LLC now owns 794,976 shares of the company’s stock valued at $1,375,000 after purchasing an additional 27,360 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its stake in shares of Taysha Gene Therapies by 110.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 59,069 shares of the company’s stock worth $102,000 after purchasing an additional 31,000 shares during the last quarter. 77.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

TSHA has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, February 27th. Chardan Capital reiterated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Stock Down 2.8 %

TSHA stock opened at $1.74 on Wednesday. The company’s 50 day simple moving average is $1.64 and its 200-day simple moving average is $1.93. Taysha Gene Therapies, Inc. has a 52-week low of $1.19 and a 52-week high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The firm has a market capitalization of $356.70 million, a P/E ratio of 2.76 and a beta of 0.91.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The company had revenue of $2.02 million during the quarter, compared to analyst estimates of $2.05 million. As a group, equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.